RTP Mobile Logo
Select Publications

Aggarwal C et al. SWOG S1400D (NCT0296 5378), a Phase II study of the fibroblast growth factor receptor inhibitor AZD4547 in previously treated patients with fibroblast growth factor pathway-activated Stage IV squamous cell lung cancer (Lung-MAP substudy). J Thorac Oncol 2019;14(10):1847-52. Abstract

Alexander M et al. The evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancer. Expert Rev Respir Med 2020:14(2):137-47. Abstract

Antonia SJ et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018;379(24):2342-50. Abstract

Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489(7417):519-25. Abstract

Edelman MJ et al. SWOG S1400C (NCT02154490) — A phase II study of palbociclib for previously treated cell cycle gene alteration-positive patients with stage IV squamous cell lung cancer (Lung-MAP substudy). J Thorac Oncol 2019;14(10):1853-9. Abstract

Gadgeel S et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol 2018;29(11):2214-22. Abstract

Gandara DR et al. In search of an oncogene driver for squamous lung cancer. JAMA Oncol 2018;4(9):1197-8. Abstract

Goss GD et al. Association of ERBB mutations with clinical outcomes of afatinib- or erlotinib-treated patients with lung squamous cell carcinoma: Secondary analysis of the LUX-Lung 8 randomized clinical trial. JAMA Oncol 2018;4(9):1189-97. Abstract

Goss G et al. Second-ine afatinib for advanced squamous cell carcinoma of the lung: Analysis of afatinib long-term responders in the phase III LUX-Lung 8 trial. IASLC 2016;Abstract OA23.03.

Hellman MD et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 2019;381(21):2020-31. Abstract

Herbst RS et al. Lung Master Protocol (Lung-MAP) — A biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res 2015;21(7):1514-24. Abstract

Lai WV et al. Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: A retrospective international multicentre study. Eur J Cancer 2019;109:28-35. Abstract

Langer CJ et al. SWOG S1400B (NCT02785913), a phase II study of GDC-0032 (taselisib) for previously treated PI3K-positive patients with Stage IV squamous cell lung cancer (Lung-MAP substudy). J Thorac Oncol 2019;14(10):1839-46. Abstract

Li BT et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: Results from a phase II basket trial. J Clin Oncol 2018;36(24):2532-7. Abstract

Pacheco JM et al. A changing of the guard: Immune checkpoint inhibitors with and without chemotherapy as first line treatment for metastatic non-small cell lung cancer. Front Oncol 2019;9:195. Abstract

Pacheco JM, Camidge DR. Is long-term survival possible for patients with stage IV ALK+ non-small cell lung cancer? Expert Rev Respir Med 2019;13(5):399-401. Abstract

Paz-Ares L et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018;379(21):2040-51. Abstract

Paz-Ares LG et al. Treatment outcomes by histology in REVEL: A randomized phase III trial of ramucirumab plus docetaxel for advanced non-small cell lung cancer. Lung Cancer 2017;112:126-33. Abstract

Peters S et al. Activity of afatinib in heavily pretreated patients with ERBB2 mutation–positive advanced NSCLC: Findings from a global named patient use program. J Thoracic Oncol 2018;13(12):1897-905. Abstract

Ready N et al. First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): Outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers. J Clin Oncol 2019;37(12):992-1000. Abstract

Reck M et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med 2019;7(5): 387-401. Abstract

Reck M et al. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: Patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. Eur J Cancer 2019;116:137-47. Abstract

Socinski MA et al; IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018;378(24):2288-301. Abstract

Soria J-C et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): An open-label randomised controlled phase III trial. Lancet Oncol 2015;16(8):897-907. Abstract

Spigel D et al. IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC. ESMO 2019;Abstract LBA78.

Sukari A et al. Cancer site and adverse events induced by immune checkpoint inhibitors: A retrospective analysis of real-life experience at a single institution. Anticancer Res 2019;39(2):781-90. Abstract

Tsurutani J et al. Updated results of phase I study of DS-8201a in HER2-expressing or mutated advanced non-small-cell lung cancer. IASLC 2018;Abstract OA02.07.

Weinberg F, Gadgeel S. Combination pembrolizumab plus chemotherapy: A new standard of care for patients with advanced non-small-cell lung cancer. Lung Cancer (Auckl) 2019;10:47-56. Abstract

Yang JC-H et al. LUX-Lung 8 phase III trial: Analysis of long-term response to second-line afatinib in patients with advanced squamous cell carcinoma (SCC) of the lung. ELCC 2017;Abstract 102P.